Shares of Immune Design Corp. (NASDAQ:IMDZ) have received an average recommendation of “Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $14.50.

A number of analysts have commented on the stock. Royal Bank Of Canada assumed coverage on shares of Immune Design Corp. in a report on Thursday. They set an “outperform” rating for the company. ValuEngine raised shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 5th. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Immune Design Corp. in a research note on Wednesday, June 28th. Finally, Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a research note on Tuesday, June 6th.

In other news, Director Lewis W. Coleman acquired 8,000 shares of Immune Design Corp. stock in a transaction dated Friday, July 7th. The stock was purchased at an average cost of $9.27 per share, with a total value of $74,160.00. Following the completion of the purchase, the director now directly owns 40,000 shares in the company, valued at approximately $370,800. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Wayne Gombotz sold 10,000 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $11.43, for a total transaction of $114,300.00. Following the completion of the sale, the insider now directly owns 33,054 shares of the company’s stock, valued at $377,807.22. The disclosure for this sale can be found here. Over the last three months, insiders bought 30,000 shares of company stock valued at $272,760. Corporate insiders own 42.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in IMDZ. Bank of America Corp DE increased its stake in shares of Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 8,418 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Immune Design Corp. in the second quarter worth $117,000. Alliancebernstein L.P. purchased a new stake in shares of Immune Design Corp. in the second quarter worth $118,000. Virtu KCG Holdings LLC purchased a new stake in shares of Immune Design Corp. in the second quarter worth $153,000. Finally, Trexquant Investment LP purchased a new stake in shares of Immune Design Corp. in the first quarter worth $183,000. 51.46% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/14/immune-design-corp-imdz-given-average-rating-of-buy-by-brokerages.html.

Shares of Immune Design Corp. (IMDZ) traded down 1.59% on Thursday, reaching $9.30. 107,948 shares of the company’s stock traded hands. The firm’s 50-day moving average is $9.76 and its 200-day moving average is $7.87. The stock’s market cap is $238.26 million. Immune Design Corp. has a 52-week low of $4.50 and a 52-week high of $13.05.

Immune Design Corp. (NASDAQ:IMDZ) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The business had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million. Analysts anticipate that Immune Design Corp. will post ($2.39) EPS for the current fiscal year.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.